Profile data is unavailable for this security.
About the company
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
- Revenue in MXN (TTM)17.47bn
- Net income in MXN1.60bn
- Incorporated1996
- Employees1.63k
- LocationGenomma Lab Internacional SAB de CVEdificio SamaraAntonio Dovali Jaime no. 70 Piso 2Colonia Santa FeALVARO OBREGON 01210MexicoMEX
- Phone+52 5 550810000
- Fax+52 5 550810000
- Websitehttps://www.genommalab.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nanjing Vazyme Biotech Co Ltd | 3.97bn | 66.82m | 26.49bn | 2.70k | 379.98 | 2.34 | -- | 6.67 | 0.0615 | 0.0615 | 3.84 | 9.97 | 0.2644 | 1.06 | 3.57 | 519,483.10 | 0.4122 | 13.16 | 0.5237 | 15.92 | 70.21 | 70.50 | 1.56 | 23.92 | 4.17 | -- | 0.1436 | 32.20 | -63.97 | 49.74 | -111.94 | -- | 48.61 | -- |
| Shenzhen Chipscreen Biosciences Co Ltd | 1.86bn | -199.20m | 26.62bn | 1.06k | -- | 5.72 | -- | 14.32 | -0.1709 | -0.1709 | 1.60 | 4.03 | 0.2022 | 2.34 | 4.47 | 620,847.90 | -2.17 | 1.32 | -2.44 | 1.54 | 86.24 | 93.29 | -10.72 | 6.97 | 2.76 | -0.5584 | 0.441 | 0.00 | -1.18 | 28.81 | 408.09 | 23.31 | 10.23 | -- |
| Guangxi Wuzhou Zhongheng Group Co Ltd | 8.09bn | -70.63m | 26.69bn | 2.89k | -- | 1.45 | -- | 3.30 | -0.0074 | -0.0074 | 0.8379 | 1.89 | 0.2476 | 2.17 | 4.52 | 990,180.10 | -0.3138 | 2.26 | -0.4836 | 3.38 | 42.33 | 72.05 | -1.27 | 7.27 | 2.39 | -- | 0.1767 | 45.67 | 14.10 | -1.26 | 6.69 | -32.76 | -4.56 | -30.12 |
| Sanofi Consumer Healthcare India Ltd | 1.91bn | 551.36m | 26.82bn | -- | 48.65 | 60.80 | 47.90 | 14.02 | 100.17 | 100.17 | 347.67 | 80.15 | -- | -- | -- | -- | -- | -- | -- | -- | 71.64 | -- | 28.81 | -- | 2.27 | 3,260.00 | 0.0986 | -- | -- | -- | -- | -- | -- | -- |
| Luye Pharma Group Ltd | 17.84bn | 2.18bn | 26.96bn | 5.23k | 12.39 | 0.7329 | 6.15 | 1.51 | 0.2237 | 0.2237 | 1.83 | 3.78 | 0.236 | 2.44 | 3.02 | 1,308,291.00 | 3.11 | 2.80 | 5.47 | 4.45 | 68.73 | 70.53 | 13.18 | 10.39 | 1.20 | 3.14 | 0.4103 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
| Cosmo Pharmaceuticals NV | 4.05bn | 1.52bn | 27.19bn | 339.00 | 16.41 | 2.28 | 14.72 | 6.71 | 4.06 | 4.06 | 10.83 | 29.19 | 0.2696 | 3.19 | 6.45 | 535,977.70 | 10.16 | 0.0615 | 12.44 | 0.0674 | 76.47 | 56.84 | 37.68 | 0.535 | 4.48 | -- | 0.0029 | 3,947.26 | -9.12 | 7.17 | -128.63 | -- | 9.62 | -- |
| GuangYuYuan Chinese Herbal Medicn Co Ltd | 3.51bn | 386.78m | 27.20bn | 1.81k | 70.33 | 6.13 | -- | 7.75 | 0.279 | 0.279 | 2.53 | 3.20 | 0.5011 | 0.5647 | 2.60 | 684,557.40 | 6.04 | -2.10 | 8.71 | -3.16 | 72.21 | 69.74 | 12.05 | -6.00 | 0.9873 | 21.00 | 0.0267 | -- | 13.56 | -4.53 | 136.03 | -24.78 | -58.35 | -- |
| Genomma Lab Internacional SAB de CV | 17.47bn | 1.60bn | 27.34bn | 1.63k | 15.81 | 2.27 | 14.55 | 1.57 | 1.69 | 1.69 | 18.48 | 11.80 | 0.7663 | 2.81 | 3.85 | 10,695,950.00 | 7.03 | 5.79 | 10.00 | 8.64 | 63.56 | 61.70 | 9.18 | 7.88 | 1.56 | 3.96 | 0.3738 | 16.85 | -2.10 | 6.90 | -21.90 | -0.4465 | -26.37 | -- |
| Cansino Biologics Inc | 2.12bn | -2.04bn | 27.68bn | 1.49k | -- | 2.73 | -- | 13.06 | -2.92 | -2.92 | 3.03 | 20.46 | 0.0851 | 0.6341 | 1.12 | 501,023.80 | -8.41 | -4.27 | -11.09 | -5.59 | 67.71 | 41.73 | -98.82 | -27.60 | 2.27 | -8.75 | 0.2934 | -- | -65.49 | 163.48 | -63.04 | -- | 30.60 | -- |
| North China Pharmaceutical Co Ltd | 27.49bn | 224.84m | 27.85bn | 10.16k | 123.15 | 1.83 | -- | 1.01 | 0.0465 | 0.0465 | 5.68 | 3.13 | 0.4492 | 2.67 | 4.34 | 955,385.00 | 0.6731 | -0.2978 | 1.54 | -0.7042 | 29.79 | 35.73 | 1.50 | -0.5985 | 0.5609 | 1.64 | 0.6482 | -- | -3.62 | 1.89 | 100.71 | -49.62 | 4.22 | -19.73 |
| Everest Medicines Ltd | 1.18bn | -2.98bn | 28.20bn | 520.00 | -- | 2.23 | -- | 23.84 | -3.57 | -3.57 | 1.42 | 15.02 | 0.0756 | 5.23 | 3.22 | 1,058,057.00 | -19.03 | -30.52 | -20.21 | -33.14 | 75.74 | -- | -251.64 | -5,745.25 | 4.62 | -- | 0.1119 | -- | 884.46 | -- | -241.50 | -- | 4.65 | -- |
| Youcare Pharmaceutical Group Co Ltd | 11.98bn | 686.15m | 28.35bn | 3.18k | 41.33 | 2.73 | -- | 2.37 | 0.5382 | 0.5382 | 9.39 | 8.14 | 0.7221 | 2.33 | 5.37 | 1,330,727.00 | 4.11 | 7.11 | 6.04 | 11.65 | 58.62 | 64.14 | 5.70 | 8.07 | 1.52 | 105.13 | 0.1939 | 60.95 | -7.61 | 1.05 | -44.84 | -7.16 | 23.40 | -- |
Data as of Nov 04 2024. Currency figures normalised to Genomma Lab Internacional SAB de CV's reporting currency: Mexican New Peso MXN
21.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 45.12m | 4.42% |
| Skagen AS (Investment Management)as of 30 Sep 2024 | 30.46m | 2.99% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 28.17m | 2.76% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 21.59m | 2.12% |
| BlackRock M�xico SA de CV Asesor en Inversiones Independienteas of 03 Oct 2024 | 17.80m | 1.75% |
| Lemanik Asset Management SAas of 30 Jun 2024 | 17.62m | 1.73% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 17.00m | 1.67% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 13.79m | 1.35% |
| Invesco Asset Management Ltd.as of 28 Jun 2024 | 12.70m | 1.25% |
| BlackRock M�xico Operadora SA de CV SOFIas of 30 Aug 2024 | 10.43m | 1.02% |
More ▼
Data from 30 Jun 2024 - 30 Oct 2024Source: FactSet Research Systems Inc.
